Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: The consequences of low-level viremia in people with HIV are unclear. We used data from the US Military HIV Natural History Study to examine the association of low-level viremia (LLV) and serious non-AIDS events (SNAEs).
Methods: Included participants initiated antiretroviral therapy after 1996 and had ≥3 viral loads (VLs) measured, using an assay with a lower limit of detection of <50 copies/mL, ≥6 months after antiretroviral therapy initiation. VLs were categorized as lower levels of LLV (51-199 copies/mL), higher level of low-level viremia (HLLV; 200-999 copies/mL), and (VF; ≥200 copies/mL on 2 or more successive determinations or a single VL ≥1000 copies/mL), and virologic suppression (VS; ie, VL <50 copies/mL). Viral blips (ie, VLs between 50 and 999 copies/mL that are preceded and succeeded by VL <50 copies/mL) were analyzed in the VS category. Cox proportional hazards models were used to examine the association of LLV and SNAEs, adjusted hazard ratios and 95% confidence intervals are presented.
Results: A total of 439 (17.4%) SNAEs were recorded among the 2528 participants (93% male, 40% Caucasian, 43% African American) followed for a median of 11 years. In 8.5% and 4.6% of the participants, respectively, LLV and HLLV were the highest recorded viremia strata. Compared with VS, SNAEs were associated with LLV (1.3 [1.2-1.4]), HLLV (1.6 [1.5-1.7]), and virologic failure (1.7 [1.7-1.8]).
Conclusions: The results of this study suggest that LLV is associated with the occurrence of SNAEs and needs further study.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11020230 | PMC |
| http://dx.doi.org/10.1093/ofid/ofae147 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Two-threshold defined immune non-responders are associated with long-term morbidity in people with HIV: a prospective cohort study.
Emerg Microbes Infect
December 2025
School of Public Health, Shenzhen University Medical School, Shenzhen, People's Republic of China.
A substantial proportion of people with HIV (PWH) fail to achieve full immune recovery despite long-term antiretroviral therapy (ART), potentially increasing their risk of serious comorbidities. This study investigated the association between immune non-responder (INR) and the incidence of AIDS-defining diseases (ADs) and non-AIDS-defining diseases (NADs) in a prospective cohort at the Third People's Hospital of Shenzhen, China. The low - and high-threshold cohorts included 7,874 and 8,077 individuals with baseline CD4 T-cell counts < 350 and < 500cells/μL, respectively.
View Article and Find Full Text PDFEffectiveness of dolutegravir-based vs boosted darunavir-based first-line 3-drug regimens in people with HIV with advanced disease: A trial emulation.
Int J Infect Dis
June 2025
Centre for Clinical Research, Epidemiology, Modelling and Evaluation, Institute for Global Health, London, UK.
Background: No randomized comparisons exist between dolutegravir (DTG) and boosted-darunavir (DRV/b) for people initiating treatment with advanced HIV.
Methods: Antiretroviral therapy (ART)-naïve people with HIV (PWH) with CD4 < 200 cells/mm or AIDS who started a first-line three-drug regimen with DTG or DRV/b were included. The primary outcome was a composite endpoint of newly diagnosed AIDS, serious non-AIDS events (SNAE), death, virological failure (VF), or discontinuation of the anchor drug due to failure or toxicity.
Increased mortality and morbidity risk in people with early HIV care interruption in Spain.
AIDS
July 2025
National Center for Epidemiology, Carlos III Health Institute.
Objective: We assessed the association between early HIV medical care interruption (MCI) and the development of AIDS-defining events (ADEs), serious non-AIDS events (SNAEs), and death among people with HIV (PWH) from the CoRIS cohort.
Design: We included antiretroviral-naive individuals aged at least 18 years at enrollment, recruited between 1 January 2004 and 30 May 2021, and followed-up until 30 November 2023.
Methods: Early MCI was defined as a time interval over 15 months between two consecutive visits, where the first of these visits occurred within the first 15 months of enrollment.
Comparison of clinical outcomes of pulmonary nocardiosis between AIDS and non-AIDS patients.
BMC Infect Dis
June 2024
Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, 10700, Thailand.
Article Synopsis
- Nocardia species can infect both healthy and immunocompromised individuals, prompting a study comparing outcomes in AIDS and non-AIDS patients with pulmonary nocardiosis in northeastern Thailand from 2009 to 2022.
- The study found that AIDS patients had higher rates of severe complications and mortality, particularly those with disseminated disease, highlighting a 7.93-fold increased risk of death within 30 days compared to non-AIDS patients.
- The authors conclude that early diagnosis and a multidrug treatment approach are crucial for managing pulmonary nocardiosis in resource-limited settings, especially for AIDS patients.
Low Level Viremia Is Associated With Serious non-AIDS Events in People With HIV.
Open Forum Infect Dis
April 2024
Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA.
Background: The consequences of low-level viremia in people with HIV are unclear. We used data from the US Military HIV Natural History Study to examine the association of low-level viremia (LLV) and serious non-AIDS events (SNAEs).
Methods: Included participants initiated antiretroviral therapy after 1996 and had ≥3 viral loads (VLs) measured, using an assay with a lower limit of detection of <50 copies/mL, ≥6 months after antiretroviral therapy initiation.